RESUMO
BACKGROUND: Patients with hematological malignancies that are highly proliferative and have high tumor burden are at high risk of developing hyperuricemia and tumor lysis syndrome (TLS), spontaneously and while undergoing chemotherapy. AIM: To assess the safety and efficacy of a new generic formulation of recombinant rasburicase in prevention and treatment of malignancy‑associated hyperuricemia. MATERIALS AND METHODS: An open‑label, multicenter, phase‑III study was conducted on 100 eligible patients with high risk for TLS. Rasburicase was administered 0.2 mg/kg intravenously over 30 min, daily, for 4 days. The outcome measures were percentage of reduction in plasma uric acid at 4 h after rasburicase, plasma uric acid area under the curve (AUC)0-96 h and incidence of adverse events. RESULTS: Eighty eight patients completed the study period of 10 days. After rasburicase administration, there was a 75.3 ± 28.5% of reduction in plasma uric acid at 4 h as compared to baseline. The plasma uric acid AUC0-96 h was 259.9 ± 215.5 mg/dL h. Safety of rasburicase was assessed on the basis of changes in vitals, hematological, and biochemical parameters from baseline to termination. Except for the plasma uric acid level, there was no significant difference in any of the parameters. Mild to moderate adverse events were reported in 29 patients. Three patients had serious adverse events (SAEs) unrelated to rasburicase. CONCLUSIONS: These results demonstrated that recombinant rasburicase that is indigenously developed is effective for prevention and management of hyperuricemia in patients who are at high risk of developing TLS.
Assuntos
Adulto , Idoso , Área Sob a Curva , Criança , Feminino , Supressores da Gota/uso terapêutico , Neoplasias Hematológicas/complicações , Humanos , Hiperuricemia/tratamento farmacológico , Hiperuricemia/etiologia , Índia , Masculino , Pessoa de Meia-Idade , Curva ROC , Síndrome de Lise Tumoral/prevenção & controle , Urato Oxidase/uso terapêutico , Ácido Úrico/sangue , Adulto JovemRESUMO
Tumor lysis syndrome is a metabolic emergency resulting from the rapid and massive destruction of tumor cells, spontaneously or secondary to cytolytic therapy for cancer. This results in a huge imbalance of internal environment by releasing large amounts of intracellular contents into the interstitial and intravascular space, with serious clinical consequences or even death. The pediatric population is especially at risk of tumor lysis syndrome because it has a high rate of fast-growing tumors, such as those of hematologic origin. Proper recognition of the risk factors that can cause this syndrome, as well as specific prevention and treatment has substantially decreased complications and improved survival in these patients.
El síndrome de lisis tumoral es una emergencia metabólica derivada de la rápida y masiva destrucción de células tumorales en forma espontánea o secundaria a terapia citolítica del cáncer. Esta situación produce un enorme desequilibrio del medio interno al liberarse grandes cantidades de contenido intracelular al espacio intersticial e intravascular, con consecuencias clínicas serias e incluso mortales. La población pediátrica está especialmente expuesta a sufrir síndrome de lisis tumoral ya que presenta una tasa elevada de tumores de rápido crecimiento, como son los de orígenes hematológicos. El adecuado reconocimiento de los factores de riesgo que pueden causar este síndrome, así como su prevención y tratamiento específicos han disminuido sustancialmente las complicaciones y mejorado la sobrevida de estos pacientes.
Assuntos
Humanos , Criança , Síndrome de Lise Tumoral/fisiopatologia , Síndrome de Lise Tumoral/terapia , Alopurinol/uso terapêutico , Hiperuricemia/etiologia , Hiperuricemia/tratamento farmacológico , Insuficiência Renal Crônica/fisiopatologia , Terapia de Substituição Renal , Fatores de Risco , Síndrome de Lise Tumoral/prevenção & controle , Síndrome de Lise Tumoral/tratamento farmacológico , Urato Oxidase/uso terapêuticoRESUMO
La gota es un tipo de artritis gatillada por la cristalización de ácido úrico dentro de las articulaciones. Múltiples factores están involucrados en su desarrollo, constituyendo actualmente la hiperuricemia una condición estrechamente relacionada con el síndrome metabólico. Los humanos carecen de una enzima que degrada el ácido úrico llamada uricasa, lo que les confiere niveles de urato más elevados que otras especies animales. Se cree que esto sería un mecanismo adaptativo que entrega protección contra diversas noxas, dadas sus propiedades antioxidantes. Los cristales de urato monosódico pueden directamente iniciar la cascada inflamatoria a través de la activación del complemento y de diversos tipos celulares. Esto genera a nivel intracelular una cascada de transducción de señales que activarán un complejo catalítico multiproteico llamado inflamasoma, el cual es clave en la activación de caspasas inflamatorias, con el consecuente clivaje proteolítico de la pro-ILl en ILl , que junto a otras citoquinas y mediadores tendrán un rol fundamental en la patogénesis de esta enfermedad. Avances en el conocimiento de esta patología han permitido identificar nuevos targets terapéuticos y desarrollar nuevas terapias que han mostrado resultados favorables en pacientes con fracaso a los tratamientos convencionales.
Gout is a type of arthritis triggered by the crystallization of uric acid in the joints. Multiple factors are involved in its development, hyperuricemia currently constitutes a condition which is closely related to the metabolic syndrome. Humans lack an enzyme that degrades uric acid called uricase, which gives us urate levels higher than other animal species. It is believed that this is an adaptive mechanism that confers protection against various noxa, given its antioxidant properties. Monosodium urate crystals can directly start the infiammatory cascade through the activation of the complement and of various cell types. This leads to a cascade of intracellular signal transduction that will activate a multiprotein catalytic complex called infiammasome, which is key in the activation of infiamatory caspases and the consequent proteolytic cleavaje of the pro-ILl in ILl, which together with other cytokines and mediators have a fundamental role in the pathogenesis of this disease. Advances in the understanding of this condition have allowed us to identify new therapeutic targets and develop new therapies that have shown favorable results in patients that do not respond to conventional treatments.